Do intraindividual variation in disease progression and the ensuing tight window of opportunity affect estimation of screening benefits?
If intraindividual variation in disease progression is ignored in decision models, subsequent cost-effectiveness analyses of screening strategies will overestimate the benefits provided by screening. This bias is comparable to, but partially independent of, the bias caused by ignoring interindividual heterogeneity.
The application of PACI during minimally invasive fetoscopic interventions seems safe for the fetal brain. Due to the still limited clinical experience with PACI, continued assessment of its maternal and fetal risks as well as management are required.